219 related articles for article (PubMed ID: 17018774)
1. Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents?
Fojo T
J Natl Cancer Inst; 2006 Oct; 98(19):1345-7. PubMed ID: 17018774
[No Abstract] [Full Text] [Related]
2. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
3. Update on tubulin-binding agents.
Attard G; Greystoke A; Kaye S; De Bono J
Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
[TBL] [Abstract][Full Text] [Related]
4. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics.
Kanakkanthara A; Teesdale-Spittle PH; Miller JH
Anticancer Agents Med Chem; 2013 Jan; 13(1):147-58. PubMed ID: 22583426
[TBL] [Abstract][Full Text] [Related]
5. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
Gökmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P; Sledge GW
Cancer Res; 2005 Oct; 65(20):9406-14. PubMed ID: 16230404
[TBL] [Abstract][Full Text] [Related]
6. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
[TBL] [Abstract][Full Text] [Related]
7. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
8. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
[TBL] [Abstract][Full Text] [Related]
9. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
10. Microtubule active agents: beyond the taxane frontier.
Morris PG; Fornier MN
Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
[TBL] [Abstract][Full Text] [Related]
11. [Progress in the study of tubulin inhibitors].
Shang H; Pan L; Yang S; Chen H; Cheng MS
Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
[TBL] [Abstract][Full Text] [Related]
12. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
[TBL] [Abstract][Full Text] [Related]
13. Microtubule alterations and resistance to tubulin-binding agents (review).
Drukman S; Kavallaris M
Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
[TBL] [Abstract][Full Text] [Related]
14. Microtubules: a dynamic target in cancer therapy.
Pasquier E; Kavallaris M
IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Tripathi S; Srivastava G; Sharma A
Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
[TBL] [Abstract][Full Text] [Related]
16. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
17. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
18. PPAR-gamma inhibitors as novel tubulin-targeting agents.
Schaefer KL
Expert Opin Investig Drugs; 2007 Jul; 16(7):923-6. PubMed ID: 17594179
[TBL] [Abstract][Full Text] [Related]
19. Characterization of HSP27 phosphorylation induced by microtubule interfering agents: implication of p38 signalling pathway.
Casado P; Zuazua-Villar P; Prado MA; Valle ED; Iglesias JM; Martínez-Campa C; Lazo PS; Ramos S
Arch Biochem Biophys; 2007 May; 461(1):123-9. PubMed ID: 17367746
[TBL] [Abstract][Full Text] [Related]
20. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]